Since March 2021, the S&P 500 has delivered a total return of 70.9%. But one standout stock has nearly doubled the market - over the past five years, Gilead Sciences has surged 127% to $145.23 per share. Its momentum hasn’t stopped as it’s also gained 27.8% in the last six months, beating the S&P by 26.8%.
Is there a buying opportunity in Gilead Sciences, or does it present a risk to your portfolio? See what our analysts have to say in our full research report, it’s free.
Why Is Gilead Sciences Not Exciting?
We’re happy investors have made money, but we don't have much confidence in Gilead Sciences. Here are three reasons there are better opportunities than GILD and a stock we'd rather own.
1. Long-Term Revenue Growth Disappoints
Examining a company’s long-term performance can provide clues about its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, Gilead Sciences grew its sales at a tepid 3.6% compounded annual growth rate. This was below our standard for the healthcare sector.
2. Free Cash Flow Margin Dropping
If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.
As you can see below, Gilead Sciences’s margin dropped by 7.5 percentage points over the last five years. If its declines continue, it could signal increasing investment needs and capital intensity. Gilead Sciences’s free cash flow margin for the trailing 12 months was 32.1%.
3. New Investments Fail to Bear Fruit as ROIC Declines
A company’s ROIC, or return on invested capital, shows how much operating profit it makes compared to the money it has raised (debt and equity).
We like to invest in businesses with high returns, but the trend in a company’s ROIC is what often surprises the market and moves the stock price. Unfortunately, Gilead Sciences’s ROIC has decreased over the last few years. We like what management has done in the past, but its declining returns are perhaps a symptom of fewer profitable growth opportunities.
Final Judgment
Gilead Sciences’s business quality ultimately falls short of our standards. With its shares outperforming the market lately, the stock trades at 16.6× forward P/E (or $145.23 per share). This valuation multiple is fair, but we don’t have much faith in the company. We're pretty confident there are superior stocks to buy right now. We’d recommend looking at the most entrenched endpoint security platform on the market.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
